Shuai Xia

Dr. Shuai Xia


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
QLQiaoshuai Lan
Qiaoshuai Lan
LWLijue Wang
Lijue Wang
FJFanke Jiao
Fanke Jiao
Lu LuLu Lu
Lu Lu
SXShuai Xia
Shuai Xia
Shibo JiangShibo Jiang
Shibo Jiang

23 February 2023 in Emerging Microbes & Infections
Verified
Journal Article
Open access
SXShuai Xia
Shuai Xia
LWLijue Wang
Lijue Wang
FJFanke Jiao
Fanke Jiao
XYXueying Yu
Xueying Yu
WXWei Xu
Wei Xu
Lu LuLu Lu
Lu Lu
Continuous emergence of the Omicron variant, along with its subvariants, has caused an increasing number of infections, reinfections, and vaccine-breakthrough infections, seriously threatening human health. Recently, several new Omicron subvariants, such as BA.5, BA.2.75, BA.4.6, and BF.7, bearing distinct mutation profiles in their spike (S) proteins, have significantly increased their capacity to evade vaccine-induced immunity and have shown enhanced infectivity and transmissibility, quickly becoming dominant sublineages. In this study, we found the S proteins of these Omicron subvariants to have 2- to 4-fold more efficient membrane fusion kinetics than that of the original Omicron variant (BA.1), indicating that these novel Omicron subvariants might possess increased pathogenicity. We also identified that peptide-based pan-CoV fusion inhibitors, EK1 and EK1C4, showed equal efficacy against membrane fusion mediated by S proteins of the noted Omicron subvariants and infection by their pseudoviruses. Additionally, either immune sera induced by wild-type (WT) SARS-CoV-2 RBD-based vaccine or BA.2 convalescent sera showed potent synergism with EK1 against both WT SARS-CoV-2 and various Omicron subvariants, further suggesting that EK1-based fusion inhibitors are promising candidates for development as clinical antiviral agents against the currently circulating Omicron subvariants.

Verified
Journal Article
Open access
PDF file
QLQiaoshuai Lan
Qiaoshuai Lan
CWChao Wang
Chao Wang
JZJie Zhou
Jie Zhou
LWLijue Wang
Lijue Wang
FJFanke Jiao
Fanke Jiao
Shibo JiangShibo Jiang
Shibo Jiang
The COVID-19 pandemic caused by SARS-CoV-2 infection poses a serious threat to global public health and the economy. The enzymatic product of cholesterol 25-hydroxylase (CH25H), 25-Hydroxycholesterol (25-HC), was reported to have potent anti-SARS-CoV-2 activity. Here, we found that the combination of 25-HC with EK1 peptide, a pan-coronavirus (CoV) fusion inhibitor, showed a synergistic antiviral activity. We then used the method of 25-HC modification to design and synthesize a series of 25-HC-modified peptides and found that a 25-HC-modified EK1 peptide (EK1P4HC) was highly effective against infections caused by SARS-CoV-2, its variants of concern (VOCs), and other human CoVs, such as HCoV-OC43 and HCoV-229E. EK1P4HC could protect newborn mice from lethal HCoV-OC43 infection, suggesting that conjugation of 25-HC with a peptide-based viral inhibitor was a feasible and universal strategy to improve its antiviral activity.

6 March 2022 in Viruses
Verified
Journal Article
Open access
PDF file
QLQiaoshuai Lan
Qiaoshuai Lan
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
WXWei Xu
Wei Xu
LWLijue Wang
Lijue Wang
FJFanke Jiao
Fanke Jiao
QWQian Wang
Qian Wang
Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting that the development of C16-based lipopeptide drugs is feasible. Here, we designed and synthesized a C16-modified pan-CoV fusion inhibitor, EK1-C16, and found that it potently inhibited infection by SARS-CoV-2 and its variants of concern (VOCs), including Omicron, and other human CoVs and bat SARS-related CoVs (SARSr-CoVs). These results suggest that EK1-C16 could be further developed for clinical use to prevent and treat infection by the currently circulating MERS-CoV, SARS-CoV-2 and its VOCs, as well as any future emerging or re-emerging coronaviruses.

9 January 2024 in Cell Discovery
Verified
Journal Article
Open access
PDF file
LWLijue Wang
Lijue Wang
FJFanke Jiao
Fanke Jiao
HJHanxiao Jiang
Hanxiao Jiang
YYYitao Yang
Yitao Yang
ZHZiqi Huang
Ziqi Huang
Lu LuLu Lu
Lu Lu

22 August 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
XSXiaojie Su
Xiaojie Su
ZHZiqi Huang
Ziqi Huang
WXWei Xu
Wei Xu
QWQian Wang
Qian Wang
LXLixiao Xing
Lixiao Xing
SXShuai Xia
Shuai Xia
The peptide-based pan-coronavirus fusion inhibitor EK1 is in phase III clinical trials, and it has, thus far, shown good clinical application prospects against SARS-CoV-2 and its variants. To further improve its in vivo long-acting property, we herein developed an Fc-binding strategy by conjugating EK1 with human immunoglobulin G Fc-binding peptide (IBP), which can exploit the long half-life advantage of IgG in vivo. The newly engineered peptide IBP-EK1 showed potent and broad-spectrum inhibitory activity against SARS-CoV-2 and its variants, including various Omicron sublineages and other human coronaviruses (HCoVs) with low cytotoxicity. In mouse models, IBP-EK1 possessed potent prophylactic and therapeutic efficacy against lethal HCoV-OC43 challenge, and it showed good safety profile and low immunogenicity. More importantly, IBP-EK1 exhibited a significantly extended in vivo half-life in rhesus monkeys of up to 37.7 h, which is about 20-fold longer than that reported for EK1. Strikingly, IBP-EK1 displayed strong in vitro or ex vivo synergistic anti-HCoV effect when combined with monoclonal neutralizing antibodies, including REGN10933 or S309, suggesting that IBP-conjugated EK1 can be further developed as a long-acting, broad-spectrum anti-HCoV agent, either alone or in combination with neutralizing antibodies, to combat the current COVID-19 pandemic or future outbreaks caused by emerging and re-emerging highly pathogenic HCoVs.